Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B GOTTLIEB

Showing results (401-410 of 523) with videos related to

Pageof 53
Sort By:
Dermatology and Therapy|March 7, 2024
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical TrialsRui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, et al.
The Journal of Investigative Dermatology|March 1, 1992
Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturationA B Gottlieb, R M Grossman, L Khandke, et al.
Current Medical Research and Opinion|May 24, 2007
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasisAlice B Gottlieb, Kevin D Cooper, Thomas S McCormick, et al.
Journal of Drugs in Dermatology : JDD|March 4, 2011
Clinical trial safety and mortality analyses in patients receiving etanercept across approved indicationsAlice B Gottlieb, Kenneth Gordon, Edward H Giannini, et al.
The British Journal of Dermatology|June 13, 2020
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studiesA Blauvelt, C Paul, P van de Kerkhof, et al.
JAMA Dermatology|August 20, 2025
Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic ArthritisAlexander Wu, Arianna Zhang, Yujia Guo, et al.
RMD Open|February 24, 2023
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritisAlice B Gottlieb, Iain B McInnes, Proton Rahman, et al.
Dermatology and Therapy|May 30, 2024
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis SeverityApril W Armstrong, Tarannum Jaleel, Joseph F Merola, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 3, 2016
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3P van de Kerkhof, L Guenther, A B Gottlieb, et al.
The New England Journal of Medicine|January 18, 2008
Etanercept treatment for children and adolescents with plaque psoriasisAmy S Paller, Elaine C Siegfried, Richard G Langley, et al.
Pageof 53

Showing results (401-410 of 523) with videos related to

Sort By:
Pageof 53
Dermatology and Therapy|March 7, 2024
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical TrialsRui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, et al.
The Journal of Investigative Dermatology|March 1, 1992
Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturationA B Gottlieb, R M Grossman, L Khandke, et al.
Current Medical Research and Opinion|May 24, 2007
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasisAlice B Gottlieb, Kevin D Cooper, Thomas S McCormick, et al.
Journal of Drugs in Dermatology : JDD|March 4, 2011
Clinical trial safety and mortality analyses in patients receiving etanercept across approved indicationsAlice B Gottlieb, Kenneth Gordon, Edward H Giannini, et al.
The British Journal of Dermatology|June 13, 2020
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studiesA Blauvelt, C Paul, P van de Kerkhof, et al.
JAMA Dermatology|August 20, 2025
Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic ArthritisAlexander Wu, Arianna Zhang, Yujia Guo, et al.
RMD Open|February 24, 2023
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritisAlice B Gottlieb, Iain B McInnes, Proton Rahman, et al.
Dermatology and Therapy|May 30, 2024
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis SeverityApril W Armstrong, Tarannum Jaleel, Joseph F Merola, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 3, 2016
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3P van de Kerkhof, L Guenther, A B Gottlieb, et al.
The New England Journal of Medicine|January 18, 2008
Etanercept treatment for children and adolescents with plaque psoriasisAmy S Paller, Elaine C Siegfried, Richard G Langley, et al.
Pageof 53